Combination therapies comprising targeted therapeutics

Abstract

The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

We claim: 
     
         1 . A method of treating cancer comprising administering SDC-TRAP-0063, its tautomer, or its salt, and at least one poly ADP ribose polymerase (PARP) inhibitor to a patient. 
     
     
         2 . The method of  claim 1 , wherein SDC-TRAP-0063, its tautomer, or its salt, is administered once per week. 
     
     
         3 . The method of  claim 1 , wherein SDC-TRAP-0063, its tautomer, or its salt, is administered intravenously. 
     
     
         4 . The method of  claim 1 , wherein SDC-TRAP-0063, its tautomer, or its salt, is administered at between around 25 to around 200 mg/kg. 
     
     
         5 . The method of  claim 4 , wherein SDC-TRAP-0063, its tautomer, or its salt, is administered at 40 mg/kg. 
     
     
         6 . The method of  claim 4 , wherein SDC-TRAP-0063, its tautomer, or its salt, is administered at 100 mg/kg. 
     
     
         7 . The method of  claim 1 , wherein the PARP inhibitor is administered once per day for 5 days per week. 
     
     
         8 . The method of  claim 1 , wherein the PARP inhibitor is talazoparib. 
     
     
         9 . The method of  claim 8 , wherein talazoparib is administered orally. 
     
     
         10 . The method of  claim 8 , wherein talazoparib is administered at around 0.3 mg/kg. 
     
     
         11 . The method of  claim 1 , wherein the PARP inhibitor is olaparib. 
     
     
         12 . The method of  claim 11 , wherein olaparib is administered orally. 
     
     
         13 . The method of  claim 11 , wherein olaparib is administered at around 50 mg/kg. 
     
     
         14 . The method of  claim 1 , wherein the cancer is selected from non-small cell lung cancer, breast cancer, and ovarian cancer. 
     
     
         15 . The method of  claim 1 , wherein the patient is BRCA1 and/or BRCA2 mutant. 
     
     
         16 . The method of  claim 1 , wherein the patient is not BRCA1 and/or BRCA2 mutant.